Figure 1From: Tolerability to romidepsin in patients with relapsed/refractory T-cell lymphoma Total adverse events (AEs) and drug-related AEs in patients with relapsed/refractory peripheral or cutaneous T-cell lymphoma (PTCL, CTCL). Back to article page